Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Next Previous
Trial Profile

An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conbercept (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Acronyms CRAVE
  • Sponsors Chengdu Kanghong Biotech

Most Recent Events

  • 11 Jul 2022 Status changed from recruiting to completed.
  • 19 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2020.
  • 19 Sep 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top